Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double-Blind, Sponsor-Open, Double-Dummy, Proof of Concept Phase 2 Study to Evaluate the Efficacy and Safety of TAK-951 Versus Ondansetron in the Prophylaxis of Postoperative Nausea and Vomiting in High-Risk Subjects

NCT04557189 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT04557189
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04557189 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double-Blind, Sponsor-Open, Double-Dummy, Proof of Concept Phase 2 Study to Evaluate the Efficacy and Safety of TAK-951 Versus Ondansetron in the Prophylaxis of Postoperative Nausea and Vomiting in High-Risk Subjects
Lead sponsor
Takeda
Phase
Phase 2
Overall status
Completed
Start date
October 20, 2020
Completion date
March 21, 2022
Enrollment
89 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

postoperative nausea and vomiting (ponv)